Clinical Trial

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Trial Details
NCT Number NCT07026149
Lead Sponsor Ruijin Hospital
Conditions Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment 30 participants
Start Date 2025-06-08
Primary Completion 2025-09-01 (estimated)
Study Completion 2030-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-18